Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

The herpesviral antagonist m152 reveals differential activation of STING-dependent IRF and NF-κB signaling and STING's dual role during MCMV infection.

Stempel M, Chan B, Juranić Lisnić V, Krmpotić A, Hartung J, Paludan SR, Füllbrunn N, Lemmermann NA, Brinkmann MM.

EMBO J. 2019 Jan 29. pii: e100983. doi: 10.15252/embj.2018100983. [Epub ahead of print]

2.

Differences between screen-detected and interval breast cancers among BRCA mutation carriers.

Pilewskie M, Zabor EC, Gilbert E, Stempel M, Petruolo O, Mangino D, Robson M, Jochelson MS.

Breast Cancer Res Treat. 2019 Jan 23. doi: 10.1007/s10549-018-05123-6. [Epub ahead of print]

PMID:
30673971
3.

Severe Infection and Loss of Leg Function From an Unusual Cutaneous Disease: Challenge.

Kamath P, Alqatari M, Stempel M, Romanelli P.

Am J Dermatopathol. 2018 Dec 7. doi: 10.1097/DAD.0000000000001331. [Epub ahead of print] No abstract available.

PMID:
30562219
4.

Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed?

Baker JL, Muhsen S, Zabor EC, Stempel M, Gemignani ML.

Ann Surg Oncol. 2019 Feb;26(2):336-342. doi: 10.1245/s10434-018-7004-6. Epub 2018 Nov 30.

PMID:
30506175
5.

Does nonmetastatic inflammatory breast cancer have a worse prognosis than other nonmetastatic T4 cancers?

Romanoff A, Zabor EC, Petruolo O, Stempel M, El-Tamer M, Morrow M, Barrio AV.

Cancer. 2018 Nov 15;124(22):4314-4321. doi: 10.1002/cncr.31757. Epub 2018 Oct 11.

PMID:
30307616
6.

Influence of Age on the Clinical Outcome of Breast Cancer for Men and the Development of Second Primary Cancers.

Cronin PA, Romanoff A, Zabor EC, Stempel M, Eaton A, Smyth LM, Ho AY, Morrow M, El-Tamer M, Gemignani ML.

Ann Surg Oncol. 2018 Dec;25(13):3858-3866. doi: 10.1245/s10434-018-6767-0. Epub 2018 Oct 8.

PMID:
30298320
7.

A Comparison of Patient-Reported Outcomes After Nipple-Sparing Mastectomy and Conventional Mastectomy with Reconstruction.

Romanoff A, Zabor EC, Stempel M, Sacchini V, Pusic A, Morrow M.

Ann Surg Oncol. 2018 Oct;25(10):2909-2916. doi: 10.1245/s10434-018-6585-4. Epub 2018 Jul 2.

PMID:
29968023
8.

Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?

Moo TA, Edelweiss M, Hajiyeva S, Stempel M, Raiss M, Zabor EC, Barrio A, Morrow M.

Ann Surg Oncol. 2018 Jun;25(6):1488-1494. doi: 10.1245/s10434-018-6429-2. Epub 2018 Mar 23.

PMID:
29572705
9.

Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.

Muhsen S, Moo TA, Patil S, Stempel M, Powell S, Morrow M, El-Tamer M.

Ann Surg Oncol. 2018 Jul;25(7):1912-1920. doi: 10.1245/s10434-018-6422-9. Epub 2018 Mar 21.

PMID:
29564588
10.

The interferon-stimulated gene product oligoadenylate synthetase-like protein enhances replication of Kaposi's sarcoma-associated herpesvirus (KSHV) and interacts with the KSHV ORF20 protein.

Bussey KA, Lau U, Schumann S, Gallo A, Osbelt L, Stempel M, Arnold C, Wissing J, Gad HH, Hartmann R, Brune W, Jänsch L, Whitehouse A, Brinkmann MM.

PLoS Pathog. 2018 Mar 2;14(3):e1006937. doi: 10.1371/journal.ppat.1006937. eCollection 2018 Mar.

11.

Does response to neo-adjuvant chemotherapy impact breast reconstruction?

Cassidy MR, Zabor EC, Stempel M, Mehrara B, Gemignani ML.

Breast J. 2018 Jul;24(4):567-573. doi: 10.1111/tbj.12977. Epub 2018 Jan 8.

PMID:
29316048
12.

Tumor Biology Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients Presenting with Locally Advanced Breast Cancer.

Gentile LF, Plitas G, Zabor EC, Stempel M, Morrow M, Barrio AV.

Ann Surg Oncol. 2017 Dec;24(13):3896-3902. doi: 10.1245/s10434-017-6085-y. Epub 2017 Sep 15.

13.

Differences Among a Modern Cohort of BRCA Mutation Carriers Choosing Bilateral Prophylactic Mastectomies Compared to Breast Surveillance.

Gilbert E, Zabor EC, Stempel M, Mangino D, Heerdt A, Pilewskie M.

Ann Surg Oncol. 2017 Oct;24(10):3048-3054. doi: 10.1245/s10434-017-5976-2. Epub 2017 Aug 1.

14.

The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype.

Pilewskie M, Zabor EC, Mamtani A, Barrio AV, Stempel M, Morrow M.

Ann Surg Oncol. 2017 Nov;24(12):3527-3533. doi: 10.1245/s10434-017-6016-y. Epub 2017 Jul 31.

15.

Erratum to: Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer.

Mamtani A, Patil S, Stempel M, Morrow M.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):691-692. doi: 10.1245/s10434-017-6004-2. No abstract available.

PMID:
28718032
16.

Standard Pathologic Features Can Be Used to Identify a Subset of Estrogen Receptor-Positive, HER2 Negative Patients Likely to Benefit from Neoadjuvant Chemotherapy.

Petruolo OA, Pilewskie M, Patil S, Barrio AV, Stempel M, Wen HY, Morrow M.

Ann Surg Oncol. 2017 Sep;24(9):2556-2562. doi: 10.1245/s10434-017-5898-z. Epub 2017 May 30.

17.

The murine cytomegalovirus M35 protein antagonizes type I IFN induction downstream of pattern recognition receptors by targeting NF-κB mediated transcription.

Chan B, Gonçalves Magalhães V, Lemmermann NAW, Juranić Lisnić V, Stempel M, Bussey KA, Reimer E, Podlech J, Lienenklaus S, Reddehase MJ, Jonjić S, Brinkmann MM.

PLoS Pathog. 2017 May 25;13(5):e1006382. doi: 10.1371/journal.ppat.1006382. eCollection 2017 May.

18.

Axillary Micrometastases and Isolated Tumor Cells Are Not an Indication for Post-mastectomy Radiotherapy in Stage 1 and 2 Breast Cancer.

Mamtani A, Patil S, Stempel M, Morrow M.

Ann Surg Oncol. 2017 Aug;24(8):2182-2188. doi: 10.1245/s10434-017-5866-7. Epub 2017 Apr 20. Erratum in: Ann Surg Oncol. 2017 Jul 17;:.

19.

Are there patients with T1 to T2, lymph node-negative breast cancer who are "high-risk" for locoregional disease recurrence?

Mamtani A, Patil S, Stempel MM, Morrow M.

Cancer. 2017 Jul 15;123(14):2626-2633. doi: 10.1002/cncr.30658. Epub 2017 Mar 23.

20.

Is Routine Axillary Imaging Necessary in Clinically Node-Negative Patients Undergoing Neoadjuvant Chemotherapy?

Barrio AV, Mamtani A, Eaton A, Brennan S, Stempel M, Morrow M.

Ann Surg Oncol. 2017 Mar;24(3):645-651. doi: 10.1245/s10434-017-5765-y. Epub 2017 Jan 27.

21.

Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?

Feliciano Y, Mamtani A, Morrow M, Stempel MM, Patil S, Jochelson MS.

Ann Surg Oncol. 2017 Jun;24(6):1492-1498. doi: 10.1245/s10434-016-5741-y. Epub 2017 Jan 5.

22.

Estimating the OncotypeDX score: validation of an inexpensive estimation tool.

Eaton AA, Pesce CE, Murphy JO, Stempel MM, Patil SM, Brogi E, Hudis CA, El-Tamer M.

Breast Cancer Res Treat. 2017 Feb;161(3):435-441. doi: 10.1007/s10549-016-4069-4. Epub 2016 Dec 7.

23.

Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age.

Radosa JC, Eaton A, Stempel M, Khander A, Liedtke C, Solomayer EF, Karsten M, Pilewskie M, Morrow M, King TA.

Ann Surg Oncol. 2017 Mar;24(3):698-704. doi: 10.1245/s10434-016-5631-3. Epub 2016 Oct 25.

24.

The diabetic foot.

Neville RF, Kayssi A, Buescher T, Stempel MS.

Curr Probl Surg. 2016 Sep;53(9):408-37. doi: 10.1067/j.cpsurg.2016.07.003. Epub 2016 Aug 11. Review. No abstract available.

PMID:
27687301
25.

How Often Is Treatment Effect Identified in Axillary Nodes with a Pathologic Complete Response After Neoadjuvant Chemotherapy?

Barrio AV, Mamtani A, Edelweiss M, Eaton A, Stempel M, Murray MP, Morrow M.

Ann Surg Oncol. 2016 Oct;23(11):3475-3480. doi: 10.1245/s10434-016-5463-1. Epub 2016 Jul 28.

26.

Early Adoption of the SSO-ASTRO Consensus Guidelines on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: Initial Experience from Memorial Sloan Kettering Cancer Center.

Rosenberger LH, Mamtani A, Fuzesi S, Stempel M, Eaton A, Morrow M, Gemignani ML.

Ann Surg Oncol. 2016 Oct;23(10):3239-46. doi: 10.1245/s10434-016-5397-7. Epub 2016 Jul 12.

27.

Impact of Body Mass Index on Clinical Axillary Nodal Assessment in Breast Cancer Patients.

McCartan D, Stempel M, Eaton A, Morrow M, Pilewskie M.

Ann Surg Oncol. 2016 Oct;23(10):3324-9. doi: 10.1245/s10434-016-5330-0. Epub 2016 Jun 23.

28.

How Beneficial is Follow-Up Mammography in Elderly Breast Cancer Survivors?

Massimino KP, Jochelson MS, Burgan IE, Stempel M, Morrow M.

Ann Surg Oncol. 2016 Oct;23(11):3518-3523. doi: 10.1245/s10434-016-5301-5. Epub 2016 Jun 15.

29.

Do LORIS Trial Eligibility Criteria Identify a Ductal Carcinoma In Situ Patient Population at Low Risk of Upgrade to Invasive Carcinoma?

Pilewskie M, Stempel M, Rosenfeld H, Eaton A, Van Zee KJ, Morrow M.

Ann Surg Oncol. 2016 Oct;23(11):3487-3493. doi: 10.1245/s10434-016-5268-2. Epub 2016 May 12.

30.

Late Axillary Recurrence After Negative Sentinel Lymph Node Biopsy is Uncommon.

Matsen C, Villegas K, Eaton A, Stempel M, Manning A, Cody HS, Morrow M, Heerdt A.

Ann Surg Oncol. 2016 Aug;23(8):2456-61. doi: 10.1245/s10434-016-5151-1. Epub 2016 Mar 8.

31.

Is Preoperative Axillary Imaging Beneficial in Identifying Clinically Node-Negative Patients Requiring Axillary Lymph Node Dissection?

Pilewskie M, Jochelson M, Gooch JC, Patil S, Stempel M, Morrow M.

J Am Coll Surg. 2016 Feb;222(2):138-45. doi: 10.1016/j.jamcollsurg.2015.11.013. Epub 2015 Nov 25.

32.

Reoperative Sentinel Lymph Node Biopsy is Feasible for Locally Recurrent Breast Cancer, But is it Worthwhile?

Ugras S, Matsen C, Eaton A, Stempel M, Morrow M, Cody HS 3rd.

Ann Surg Oncol. 2016 Mar;23(3):744-8. doi: 10.1245/s10434-015-5003-4. Epub 2015 Dec 7.

33.

Does a Positive Axillary Lymph Node Needle Biopsy Result Predict the Need for an Axillary Lymph Node Dissection in Clinically Node-Negative Breast Cancer Patients in the ACOSOG Z0011 Era?

Pilewskie M, Mautner SK, Stempel M, Eaton A, Morrow M.

Ann Surg Oncol. 2016 Apr;23(4):1123-8. doi: 10.1245/s10434-015-4944-y. Epub 2015 Nov 9.

34.

Breast Cancer in the Elderly: Is MRI Helpful?

Pilewskie M, Hirsch A, Eaton A, Stempel M, Gemignani ML.

Breast J. 2015 Nov-Dec;21(6):651-7. doi: 10.1111/tbj.12504. Epub 2015 Sep 24.

35.

Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.

Karsten M, Stempel M, Radosa J, Patil S, King TA.

Ann Surg Oncol. 2016 Feb;23(2):471-6. doi: 10.1245/s10434-015-4841-4. Epub 2015 Sep 4.

36.

Nipple-sparing mastectomy in patients with BRCA1/2 mutations and variants of uncertain significance.

Manning AT, Wood C, Eaton A, Stempel M, Capko D, Pusic A, Morrow M, Sacchini V.

Br J Surg. 2015 Oct;102(11):1354-9. doi: 10.1002/bjs.9884. Epub 2015 Aug 27.

37.

Breast-Conserving Surgery in Bilateral Breast Cancer.

O'Brien JA, Ho A, Wright GP, Stempel M, Patil S, Krause K, Morrow M, Gemignani ML.

Ann Surg Oncol. 2015 Oct;22(10):3389-96. doi: 10.1245/s10434-015-4746-2. Epub 2015 Aug 12.

38.

Skin Flap Necrosis After Mastectomy With Reconstruction: A Prospective Study.

Matsen CB, Mehrara B, Eaton A, Capko D, Berg A, Stempel M, Van Zee KJ, Pusic A, King TA, Cody HS 3rd, Pilewskie M, Cordeiro P, Sclafani L, Plitas G, Gemignani ML, Disa J, El-Tamer M, Morrow M.

Ann Surg Oncol. 2016 Jan;23(1):257-64. doi: 10.1245/s10434-015-4709-7. Epub 2015 Jul 21.

39.

Do the ACOSOG Z0011 Criteria Affect the Number of Sentinel Lymph Nodes Removed?

Subhedar P, Stempel M, Eaton A, Morrow M, Gemignani ML.

Ann Surg Oncol. 2015 Dec;22 Suppl 3:S470-5. doi: 10.1245/s10434-015-4698-6. Epub 2015 Jul 16.

40.

Extent of microinvasion in ductal carcinoma in situ is not associated with sentinel lymph node metastases.

Matsen CB, Hirsch A, Eaton A, Stempel M, Heerdt A, Van Zee KJ, Cody HS 3rd, Morrow M, Plitas G.

Ann Surg Oncol. 2014 Oct;21(10):3330-5. doi: 10.1245/s10434-014-3920-2. Epub 2014 Aug 5.

41.

Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement.

Ugras S, Stempel M, Patil S, Morrow M.

Ann Surg Oncol. 2014 Nov;21(12):3780-6. doi: 10.1245/s10434-014-3851-y. Epub 2014 Jun 21.

42.

The effect of metformin on breast cancer outcomes in patients with type 2 diabetes.

Oppong BA, Pharmer LA, Oskar S, Eaton A, Stempel M, Patil S, King TA.

Cancer Med. 2014 Aug;3(4):1025-34. doi: 10.1002/cam4.259. Epub 2014 Jun 18.

43.

The extent of extracapsular extension may influence the need for axillary lymph node dissection in patients with T1-T2 breast cancer.

Gooch J, King TA, Eaton A, Dengel L, Stempel M, Corben AD, Morrow M.

Ann Surg Oncol. 2014 Sep;21(9):2897-903. doi: 10.1245/s10434-014-3752-0. Epub 2014 Apr 29.

44.

Impact of molecular subtype on locoregional recurrence in mastectomy patients with T1-T2 breast cancer and 1-3 positive lymph nodes.

Moo TA, McMillan R, Lee M, Stempel M, Ho A, Patil S, El-Tamer M.

Ann Surg Oncol. 2014 May;21(5):1569-74. doi: 10.1245/s10434-014-3488-x. Epub 2014 Feb 1.

45.

Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy.

Pilewskie M, Ho A, Orell E, Stempel M, Chen Y, Eaton A, Patil S, Morrow M.

Ann Surg Oncol. 2014 Apr;21(4):1209-14. doi: 10.1245/s10434-013-3416-5. Epub 2013 Dec 11.

46.

Pharmacologic prophylaxis, postoperative INR, and risk of venous thromboembolism after hepatectomy.

Nathan H, Weiss MJ, Soff GA, Stempel M, Dematteo RP, Allen PJ, Kingham TP, Fong Y, Jarnagin WR, D'Angelica MI.

J Gastrointest Surg. 2014 Feb;18(2):295-302; discussion 302-3. doi: 10.1007/s11605-013-2383-2. Epub 2013 Oct 16.

PMID:
24129829
47.

Axillary dissection can be avoided in the majority of clinically node-negative patients undergoing breast-conserving therapy.

Dengel LT, Van Zee KJ, King TA, Stempel M, Cody HS, El-Tamer M, Gemignani ML, Sclafani LM, Sacchini VS, Heerdt AS, Plitas G, Junqueira M, Capko D, Patil S, Morrow M.

Ann Surg Oncol. 2014 Jan;21(1):22-7. doi: 10.1245/s10434-013-3200-6. Epub 2013 Aug 22.

48.

Selection criteria for postmastectomy radiotherapy in t1-t2 tumors with 1 to 3 positive lymph nodes.

Moo TA, McMillan R, Lee M, Stempel M, Patil S, Ho A, El-Tamer M.

Ann Surg Oncol. 2013 Oct;20(10):3169-74. doi: 10.1245/s10434-013-3117-0. Epub 2013 Aug 22.

PMID:
23975289
49.

Radioactive seed localization compared to wire localization in breast-conserving surgery: initial 6-month experience.

Murphy JO, Moo TA, King TA, Van Zee KJ, Villegas KA, Stempel M, Eaton A, St Germain JM, Morris E, Morrow M.

Ann Surg Oncol. 2013 Dec;20(13):4121-7. doi: 10.1245/s10434-013-3166-4. Epub 2013 Aug 14.

50.

Long-term patient-reported satisfaction after contralateral prophylactic mastectomy and implant reconstruction.

Koslow S, Pharmer LA, Scott AM, Stempel M, Morrow M, Pusic AL, King TA.

Ann Surg Oncol. 2013 Oct;20(11):3422-9. doi: 10.1245/s10434-013-3026-2. Epub 2013 May 30.

PMID:
23720070

Supplemental Content

Loading ...
Support Center